Register now: Discover areas of opportunity in CGT drug discovery
Join the DDW Cell & Gene Therapy Showcase on 21 November at 2pm GMT, a free online event hosted by DDW and supported by Benchling, Sartorius, Applied StemCell, and Elegen Bio.
In this free online event leading industry figures will outline areas of opportunity in CGT drug discovery and development sector as well as highlighting challenges facing the industry and how they can be overcome.
The first presentation will be from Victor Dillard, Vice President of Strategy & Operations of Resolution Therapeutics, and the second will be a joint presentation from Dolores Grosso, Clinical Development Lead at Tevogen Bio and Neal Flomenberg, Chair, Corporate Board and Chief Scientific Officer at Tevogen Bio.
Presentations will cover areas such as the complexities of an unclear and rapidly evolving regulatory framework for cell and gene therapies, offering examples of how to navigate the investigational new drug (IND) submission process. They will also cover how next-generation gene synthesis technology is helping to advance areas such as TCR engineering, CAR-T therapies, gene editing, and mRNA vaccines.
The panel is made up of:
- Lara Campana, Vice President of Research Operations, Resolution Therapeutics
- Dr Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
- Haley Merritt, Scientific Solutions Consultant, Benchling
- Galit Meshulam-Simon, Associate Director of Commercial Applications, Elegen Bio
- Tim Largen, Chief Operating Officer, Applied StemCell
- Hinnah Campwala, Principal Scientist, Sartorius
The panel discussion will cover areas including:
- Making use of new drug discovery and development technology, concepts and tools in CGT
- What will the future of innovative CGT therapies be and how to plan now for opportunity?
- Where are the global CGT hotspots for research, funding and clinical trials?
Register for free now to secure your place!